Enanta Pharmaceuticals (ENTA) Total Liabilities (2012 - 2026)

Enanta Pharmaceuticals' Total Liabilities history runs 15 years deep, the most recent figure standing at $198.1 million for Q1 2026.

• Quarterly Total Liabilities fell 13.66% year-over-year to $198.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.1 million (down 13.66% YoY) and the FY2025 annual result came in at $216.0 million, down 12.84% from the prior year.
• Total Liabilities was $198.1 million for Q1 2026 at Enanta Pharmaceuticals, down from $202.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $257.3 million in Q2 2023 and bottomed at $46.7 million in Q4 2022.
• A 5-year average of $179.0 million and a median of $221.8 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities declined 16.92% — and 2023, when it soared 445.34%.
• Enanta Pharmaceuticals' Total Liabilities stood at $46.7 million in 2022, then jumped by 406.7% to $236.6 million in 2023, then gained by 0.09% to $236.8 million in 2024, then declined by 14.32% to $202.9 million in 2025, then fell by 2.36% to $198.1 million in 2026.
• Business Quant data shows ENTA's Total Liabilities at $198.1 million in Q1 2026, $202.9 million in Q4 2025, and $216.0 million in Q3 2025.